However, despite the success in preclinical models, clinical trials of anti-TGFβ combined with ICIs in several solid cancers, including CRC, have suggested that this approach may be limited, as the addition of TGFβ inhibitors often failed to show meaningful clinical benefits beyond ICIs alone in unselected patients [20]. Here, TGFB1 is linked to colorectal carcinoma.